Molecular Cancer Therapeutics

Table of Contents

AACR American Association for Cancer Research

August 2015 • Volume 14 • Number 8

Table of Contents

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

There is an unmet medical need for pharmacological inhibitors of signal transducer and activator of transcription 5a/b (Stat5a/b). Stat5a/b is critical for growth and progression of solid tumors and hematological malignancies, specifically prostate cancer and Bcr-Abl–driven leukemias. IST5-002, a lead compound of a small molecule inhibitor family of Stat5a/b, was identified through structure-based *in-silico* screening and medicinal chemistry. IST5-002 potently inhibited molecular events associated with Stat5a/b activation, reduced the expression of Stat5a/b-regulated genes and induced extensive apoptotic cell death in multiple models of prostate cancer and chronic myeloid leukemias *in vitro*, *in vivo*, and in patient samples. IST5-002 provides a lead structure for further chemical modifications for clinical development. For details, see article by Liao et al., on page 1777.



Molecular Cancer Therapeutics

14 (8)

Mol Cancer Ther 2015;14:1765-1971.